Owen Mumford's drug delivery medical device, UniSafe, has achieved rapid early growth in combination product sales throughout Japan.
This follows the company's exclusive distribution agreement with Japanese pharmaceutical distributor, Nipro, which commenced in 2019 and saw the launch of UniSafe in late 2023.
UniSafe is designed to deliver a biosimilar medicine for use alongside cancer therapeutics.
During its time on the market, UniSafe has "exceeded expectations" in commercial acceptance and sales in Japan.
The biosimilar product is delivered through Owen Mumford’s UniSafe safety syringe, which is a springless and passive safety device for 1mL pre-filled syringes.
Owen Mumford designed the product to overcome hurdles associated with traditional spring-based systems — meaning the product is reliable, intuitive and easy to use.
The secure plunger's design has been crafted to prevent re-use, while also reducing the likelihood of needlestick injury.
Masanobu Iwasa, Director PharmaPackaging Division at NIPRO, commented: “Japan has a particularly stringent regulatory environment, and so that makes our rapid and early success with the product all the more gratifying. Our careful development process, in tandem with our Owen Mumford partnership, has clearly appealed to clinicians and their patients alike. The product’s rapid take-up shows that we are meeting a true market demand.”
Tim Holden, Commercial Head, Pharmaceutical Services at Owen Mumford added: “We are very committed to the Japanese market, with an established presence that has recently been greatly enhanced through our partnership with NIPRO over UniSafe. Healthcare in Japan is growing strongly, with healthcare spending rising by over a fifth between 2018 and 2025[i]. In partnership with NIPRO, we intend to continue bringing innovative therapies to Japanese patients.”